Aktis Oncology, Inc. AKTS R2K
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -85.2% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AKTS Aktis Oncology, Inc. R2K | 20.74 | - | $1.15B | - | -31.96% | - | - | -85.15% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 933.00K | 1.45M | 1.87M | 3.23M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 16.57M | 19.59M | 19.25M | 25.93M |
| Operating Income | -15.63M | -18.14M | -17.38M | -22.71M |
| EBITDA | -15.19M | -17.66M | -16.68M | -22.05M |
| Interest Expense | - | - | - | - |
| Pretax Income | -12.06M | -14.98M | -15.14M | -18.32M |
| Tax Provision | - | - | - | - |
| Net Income | -12.06M | -14.98M | -15.14M | -18.32M |
| Diluted EPS | - | -0.43 | - | -0.38 |
| R&D Expense | - | 15.86M | - | 20.04M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 1.49M | 6.50M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 19.76M | 34.79M | 53.54M | 81.18M |
| Operating Income | -19.76M | -34.79M | -52.05M | -74.68M |
| EBITDA | -19.32M | -33.60M | -50.48M | -72.36M |
| Interest Expense | - | - | - | - |
| Pretax Income | -17.93M | -28.64M | -43.98M | -63.73M |
| Tax Provision | - | - | - | - |
| Net Income | -17.93M | -28.64M | -43.98M | -63.73M |
| Diluted EPS | -0.51 | -0.82 | -1.26 | -1.21 |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 123.00% |
Compounded Profit Growth
| 5 Years: | -85.15% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -7.41% |
| 6 Months: | - |
| 3 Months: | +3.03% |
| 1 Month: | +10.79% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 138.32M | 122.36M | 326.18M | 264.88M |
| Current Assets | 132.48M | 100.20M | 300.85M | 230.31M |
| Cash & Equivalents | 128.60M | 29.51M | 37.16M | 37.78M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 157.55M | 168.66M | 413.98M | 411.03M |
| Current Liabilities | 5.28M | 6.24M | 18.82M | 31.24M |
| Long Term Debt | - | - | - | - |
| Total Debt | 1.77M | 13.40M | 12.01M | 11.55M |
| Total Equity | -19.23M | -46.31M | -87.80M | -146.15M |
| Shares Outstanding | 52.52M | 52.52M | 52.52M | 52.52M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -18.12M | -30.00M | 14.76M | -64.13M |
| Investing Cash Flow | -2.31M | -68.83M | -190.40M | 65.96M |
| Financing Cash Flow | 119.98M | 0 | 183.28M | -1.21M |
| Capital Expenditure | -2.31M | -3.76M | -2.86M | -9.58M |
| Free Cash Flow | -20.43M | -33.77M | 11.90M | -73.71M |
| Net Change in Cash | 99.55M | -98.83M | 7.65M | 625.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | -3,500.3% | -1,149.5% |
| Net Margin % | - | - | -2,957.6% | -980.9% |
| ROE % | 93.2% | 61.9% | 50.1% | 43.6% |
| ROCE % | -14.9% | -30.0% | -16.9% | -32.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | MPM Bioimpact LLC | 9.06% | 4.84M | $100.30M |
| 2 | EcoR1 Capital, LLC | 9.03% | 4.82M | $100.06M |
| 3 | Blue Owl Capital Holdings LP | 5.92% | 3.16M | $65.57M |
| 4 | Wellington Management Group, LLP | 4.34% | 2.32M | $48.06M |
| 5 | T. Rowe Price Investment Management, Inc. | 3.98% | 2.12M | $44.05M |
| 6 | Blackrock Inc. | 3.95% | 2.11M | $43.81M |
| 7 | RTW Investments LP | 2.98% | 1.59M | $33.02M |
| 8 | Price (T.Rowe) Associates Inc | 2.93% | 1.56M | $32.44M |
| 9 | RA Capital Management, L.P. | 2.81% | 1.50M | $31.17M |
| 10 | Janus Henderson Group PLC | 2.72% | 1.45M | $30.16M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AKTS